Literature DB >> 8531126

Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration.

R M Craft1, S R Henley, R C Haaseth, V J Hruby, F Porreca.   

Abstract

Antinociceptive effects of systemically or locally administered opioid mu, kappa and delta agonists were evaluated in a rat model of visceral pain. Resiniferatoxin (RTX, 3 nmol), a capsaicin-like mutant, produced abdominally directed grooming behavior after direct administration into the urinary bladder (intravesical, Lves.) by indwelling cannula. Systemic (s.c. or i.p.) pretreatment with the mu agonists morphine or [D-Ala2, NMePhe4, Gly-ol]enkephalin (Damgo), the kappa agonists trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl] benzeneacetamide (U50,488) or [5R-(5,7,8-beta)]-N-methyl-N-[7-(1-pyrrolidinyl)1-oxaspiro[4,5]dec - 8-yl]-4-benzofuranacetamide (CI-977), or the nonpeptidic delta agonist (+/-)-4-((alpha-R*)-alpha-((2S*,5R(*)-4-Allyl-2,5-dimethyl-1- piperazinyl)-3-hydroxybenzyl)-N, N-diethylbenzamide (BW373U86) dose-dependently decreased RTX-induced abdominal licking; such antinociception was selectively blocked by the appropriate receptor-selective antagonists beta-funaltrexamine (mu), nor-binaltorphimine (kappa) and naltrindole (delta). Local (i.ves.) BW373U86, [D-Ala2,Glu4]deltorphin (DELT II) and Cl-977 also significantly decreased RTX-induced licking. Intracerabroventricular quaternary naloxone partially blocked the effects of systemic morphine, but not that of CI-977 or BW373U86. Intraperitoneal quaternary naloxone blocked the effect of local and systemic BW373U86 but not that of local or systemic CI-977; systemic morphine was partially blocked. Thus, systemic mu, kappa and delta agonists all produced antinociception against a novel visceral chemical stimulus in the rat. Local CI-977 also produced antinociception, but the only compound clearly acting at peripheral opioid receptors was BW373U86, a delta agonist. This study suggests that opioid delta receptors may be present on bladder nociceptive afferents and may be activated for production of peripheral analgesia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8531126

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral delta-opioid receptors.

Authors:  Katsumi Shinoda; Victor J Hruby; Frank Porreca
Journal:  Neurosci Lett       Date:  2006-11-15       Impact factor: 3.046

2.  Oxidative damage and sensitivity to nociceptive stimulus and opioids in aging rats.

Authors:  Atul Raut; Anna Ratka
Journal:  Neurobiol Aging       Date:  2007-11-07       Impact factor: 4.673

Review 3.  Peripheral mechanisms of pain and analgesia.

Authors:  Christoph Stein; J David Clark; Uhtaek Oh; Michael R Vasko; George L Wilcox; Aaron C Overland; Todd W Vanderah; Robert H Spencer
Journal:  Brain Res Rev       Date:  2008-12-31

4.  Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.

Authors:  S Stevens Negus; Marisa B Rosenberg; Ahmad A Altarifi; Robert H O'Connell; John E Folk; Kenner C Rice
Journal:  J Pain       Date:  2012-03-15       Impact factor: 5.820

5.  Developing Improved Translational Models of Pain: A Role for the Behavioral Scientist.

Authors:  Sarah L Withey; David R Maguire; Brian D Kangas
Journal:  Perspect Behav Sci       Date:  2020-01-03

6.  Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418.

Authors:  Quan Wen; Gang Yu; Yu-lei Li; Ling-di Yan; Ze-hui Gong
Journal:  Acta Pharmacol Sin       Date:  2011-08-22       Impact factor: 6.150

7.  A rat knockout model implicates TRPC4 in visceral pain sensation.

Authors:  K N Westlund; L P Zhang; F Ma; R Nesemeier; J C Ruiz; E M Ostertag; J S Crawford; K Babinski; M M Marcinkiewicz
Journal:  Neuroscience       Date:  2014-01-03       Impact factor: 3.590

8.  Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin.

Authors:  Hitoshi Yokoyama; Katsumi Sasaki; Michael E Franks; William F Goins; James R Goss; William C de Groat; Joseph C Glorioso; Michael B Chancellor; Naoki Yoshimura
Journal:  Hum Gene Ther       Date:  2009-01       Impact factor: 5.695

9.  Effects of intravesical instillation of resiniferatoxin on bladder function and nociceptive behavior in freely moving, conscious rats.

Authors:  Chikashi Saitoh; Michael B Chancellor; William C de Groat; Naoki Yoshimura
Journal:  J Urol       Date:  2007-11-19       Impact factor: 7.450

10.  Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain.

Authors:  W F Goins; J R Goss; M B Chancellor; W C de Groat; J C Glorioso; N Yoshimura
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.